If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksINS.L Regulatory News (INS)

  • There is currently no data for INS

First Contract Win for Instem Clinical

2 Jul 2013 07:00

RNS Number : 3502I
Instem plc
02 July 2013
 

2 July 2013

Embargoed for 07:00

Instem plc

("Instem", the "Company" or the "Group")

First Contract Win for Instem Clinical

Instem plc (AIM: INS.L), a leading provider of IT applications to the global early development healthcare market, is pleased to announce its first contract win for its newly acquired ALPHADAS software. The contract consists of a high six-figure GBP perpetual licence plus implementation services, with ongoing annual support and maintenance.

ALPHADAS,the market leading, e-source data capture ("EDC") system and site automation software suite for early phase clinical studies, has been selected by a UK-based global leader in the provision of specialisedclinical services. ALPHADAS is now offered by Instem Clinical, formerly Logos Technologies, which was acquired by Instem in May 2013.

Replacing a more traditional 'form based' EDC system, ALPHADAS was selected for its ability to deliver an immediate and significant return on investment within the client's highly complex studies. ALPHADAS sources data direct from instrumentation, removes errors at source, tracks samples from collection to dispatch and enables critical real time data review. Further efficiencies are also delivered by ALPHADAS through its ability to track study subjects throughout the recruitment process, staff resourcing and site management and the provision of a fully visible audit trail.

Phil Reason, CEO of Instem plc, commented, "We are delighted to be able to announce a significant contract win for Instem Clinical, so quickly after it was established following the acquisition of Logos in May this year. A leader in their field and experiencing significant growth, the new client is currently working with some of the world's foremost pharmaceutical and research companies. This is a clear demonstration of the quality of the ALPHADAS software and the opportunity to expand Instem's market to early clinical studies."

For further information, please contact:

Instem plc

+44 (0) 1785 825 600

Phil Reason, CEO

Nigel Goldsmith, CFO

N+1 Singer (Nominated Adviser & Broker)

+44 (0) 20 7496 3000

Aubrey Powell

Joe Stroud

Newgate Threadneedle

+44 (0) 20 7653 9850

Caroline Evans-Jones

Fiona Conroy

 

About Instem plc

Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are used by customers worldwide, meeting the rapidlyexpanding needs of life science and healthcare organisations for data-driven decision making leading to safer, more effective products.

Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

Instem supports its clients through full service offices in the United States, United Kingdom and China with additional locations in India and a full service distributor based in Japan.

To learn more about Instem solutions and its mission, please visit www.instem.com or its investor centre http://investors.instem.com/

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTUGUAWMUPWPGG
Date   Source Headline
1st Sep 20217:00 amRNSAcquisition of PDS Pathology Data Systems
19th Jul 20217:00 amRNSHalf Year Trading Update
16th Jun 20213:30 pmRNSHolding(s) in Company
14th Jun 20217:00 amRNSNotice of Capital Markets Day
27th May 20213:48 pmRNSResult of AGM
20th May 20214:56 pmRNSHolding(s) in Company
11th May 202111:52 amRNSHolding(s) in Company
5th May 20217:32 amRNSHolding(s) in Company
20th Apr 20214:45 pmRNSExercise of Options, Issue of Equity and TVR
19th Apr 202112:10 pmRNSGrant of Options
19th Apr 20217:00 amRNSHolding(s) in Company
15th Apr 20215:45 pmRNSHolding(s) in Company
12th Apr 20217:00 amRNSFinal Results
1st Apr 20214:30 pmRNSCompletion of Acquisition of d-wise
30th Mar 20217:00 amRNSNotice of Results
22nd Mar 20217:00 amRNSAcquisition of d-wise and Investor Presentation
1st Mar 20217:00 amRNSAcquisition of The Edge
14th Jan 20217:00 amRNSTrading Update
15th Dec 20207:00 amRNSNew Business Update
27th Oct 20207:00 amRNSInvestor Presentation
28th Sep 20207:00 amRNSHalf-year Report
15th Sep 20207:00 amRNSNotice of Results
9th Sep 202012:14 pmRNSHolding(s) in Company
13th Aug 202012:40 pmRNSHolding(s) in Company
22nd Jul 202010:27 amRNSHolding(s) in Company
21st Jul 202011:53 amRNSHolding(s) in Company
20th Jul 20205:37 pmRNSHolding(s) in Company
20th Jul 20205:36 pmRNSHolding(s) in Company
20th Jul 202011:52 amRNSHolding(s) in Company
20th Jul 20207:00 amRNSHalf Year Trading Update
17th Jul 20203:42 pmRNSHolding(s) in Company
17th Jul 202012:38 pmRNSHolding(s) in Company
17th Jul 202012:34 pmRNSHolding(s) in Company
17th Jul 20209:15 amRNSDirector/PDMR Dealings
16th Jul 202012:27 pmRNSResult of General Meeting, Issue of Equity and TVR
8th Jul 20207:00 amRNSInvestor Communications
3rd Jul 20203:54 pmRNSHolding(s) in Company
30th Jun 20205:33 pmRNSPublication of Circular and Notice of GM
30th Jun 20202:56 pmRNSResult of AGM
26th Jun 20202:00 pmRNSResult of Placing
26th Jun 20207:00 amRNSProposed Placing
3rd Jun 20207:01 amRNSContract Win
3rd Jun 20207:00 amRNSFinal Results
29th May 20207:00 amRNSNotice of Results
25th Mar 20207:00 amRNSUpdate to Results Announcement Date
24th Feb 20207:00 amRNSNotice of Results
13th Feb 202010:40 amRNSExercise of Options/Issue of Equity
13th Jan 20207:00 amRNSTrading Update
16th Dec 20195:48 pmRNSExercise of Options and Total Voting Right
18th Nov 201910:40 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.